US2021009628A1PendingUtilityA1

Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT

76
Assignee: ATEA PHARMACEUTICALS INCPriority: Mar 6, 2015Filed: Sep 22, 2020Published: Jan 14, 2021
Est. expiryMar 6, 2035(~8.6 yrs left)· nominal 20-yr term from priority
Inventors:Jean-Pierre SommadossiAdel Moussa
A61K 31/7076A61P 31/14C07H 19/16C07H 19/20C07H 19/207
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A compound of the Formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.

Join the waitlist — get patent alerts

Track US2021009628A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.